TABLE 3.
Changes in VISA susceptibility from the baseline at 24 ha
| Multiple of MIC | Change in VISA susceptibility (log10 CFU/ml) |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MU50 |
NJ992 |
|||||||||||||
| TD-1792 | TD-1792 + S | DAP | DAP + S | VAN | LIN | QD | TD-1792 | TD-1792 + S | DAP | DAP + S | VAN | LIN | QD | |
| 4 | 3.77b | 3.05b | 3.02b | 4.01b | 2.71 | 3.19 | 2.16 | 3.84 | 3.61 | 3.61b | 4.78b | 2.88 | 2.13 | 3.65 |
| 8 | 4.33 | 3.6 | 4.82 | 4.13 | 3.32 | 3.26 | 3.82 | 4.48 | 4.09 | 3.86b | 5.01b | 4.30 | 3.66 | 3.73 |
| 16 | 4.94 | 4.37 | 5.12 | 5.09 | 4.48 | 4.25 | 4.60 | 4.94 | 4.76 | 4.68 | 5.03 | 4.58 | 3.98 | 4.47 |
| 32 | 4.92 | 4.81 | 5.12 | 5.23 | 4.41 | 4.80 | 4.97 | 5.00 | 4.92 | 4.93 | 5.04 | 4.79 | 4.89 | 4.96 |
a
DAP, daptomycin; VAN, vancomycin; QD, quinupristin-dalfopristin; LNZ, linezolid; S, 50% human serum.
b
Significant differences (P < 0.05) between TD-1792 or daptomycin with and without serum.